359 related articles for article (PubMed ID: 33584245)
1. The Neuroimmunology of Guillain-Barré Syndrome and the Potential Role of an Aging Immune System.
Hagen KM; Ousman SS
Front Aging Neurosci; 2020; 12():613628. PubMed ID: 33584245
[TBL] [Abstract][Full Text] [Related]
2. Low-Dose Exposure to Ganglioside-Mimicking Bacteria Tolerizes Human Macrophages to Guillain-Barré Syndrome-Associated Antigens.
Patry RT; Essler L; Andresen S; Quinn FD; Szymanski CM
mBio; 2021 Feb; 13(1):e0385221. PubMed ID: 35100875
[TBL] [Abstract][Full Text] [Related]
3. Beneficial or Harmful Role of Macrophages in Guillain-Barré Syndrome and Experimental Autoimmune Neuritis.
Shen D; Chu F; Lang Y; Geng Y; Zheng X; Zhu J; Liu K
Mediators Inflamm; 2018; 2018():4286364. PubMed ID: 29853789
[TBL] [Abstract][Full Text] [Related]
4. Dissecting the Role of Anti-ganglioside Antibodies in Guillain-Barré Syndrome: an Animal Model Approach.
Asthana P; Vong JS; Kumar G; Chang RC; Zhang G; Sheikh KA; Ma CH
Mol Neurobiol; 2016 Sep; 53(7):4981-91. PubMed ID: 26374552
[TBL] [Abstract][Full Text] [Related]
5. Tumor necrosis factor-α in Guillain-Barré syndrome, friend or foe?
Wang Y; Zhang J; Luo P; Zhu J; Feng J; Zhang HL
Expert Opin Ther Targets; 2017 Jan; 21(1):103-112. PubMed ID: 27817222
[TBL] [Abstract][Full Text] [Related]
6. Antiganglioside antibodies and their pathophysiological effects on Guillain-Barré syndrome and related disorders--a review.
Kaida K; Ariga T; Yu RK
Glycobiology; 2009 Jul; 19(7):676-92. PubMed ID: 19240270
[TBL] [Abstract][Full Text] [Related]
7. Detection of anti-ganglioside antibodies in Guillain-Barré syndrome.
Zhu W; Li K; Cui T; Yan Y
Ann Transl Med; 2023 Apr; 11(7):289. PubMed ID: 37090048
[TBL] [Abstract][Full Text] [Related]
8. The prediction effects of thyroid function in the severity of Guillain-Barré syndrome.
Kong L; Wu X; Cheng Y; Liu S; Liu K; Li C
Neurol Sci; 2022 Aug; 43(8):5017-5028. PubMed ID: 35469074
[TBL] [Abstract][Full Text] [Related]
9. A Guillain-Barré syndrome-associated SIGLEC10 rare variant impairs its recognition of gangliosides.
Alborzian Deh Sheikh A; Gomaa S; Li X; Routledge M; Saigoh K; Numoto N; Angata T; Hitomi Y; Takematsu H; Tsuiji M; Ito N; Kusunoki S; Tsubata T
J Autoimmun; 2021 Jan; 116():102571. PubMed ID: 33223341
[TBL] [Abstract][Full Text] [Related]
10. [Autoantibodies in Guillain-Barré Syndrome].
Uchibori A; Chiba A
Brain Nerve; 2015 Nov; 67(11):1347-57. PubMed ID: 26560950
[TBL] [Abstract][Full Text] [Related]
11. Clinical relevance of serum antibodies to GD1b in immune-mediated neuropathies.
Taams NE; Notermans NC; Fokkink WR; Tio-Gillen AP; Huizinga R; Schreurs MWJ; Jacobs BC
J Peripher Nerv Syst; 2018 Dec; 23(4):227-234. PubMed ID: 30101437
[TBL] [Abstract][Full Text] [Related]
12. [Pathophysiological and diagnostic aspects of Guillain-Barré syndrome].
Carpentier VT; Le Guennec L; Fall SAA; Viala K; Demeret S; Weiss N
Rev Med Interne; 2022 Jul; 43(7):419-428. PubMed ID: 34998626
[TBL] [Abstract][Full Text] [Related]
13. A new animal model of spontaneous autoimmune peripheral polyneuropathy: implications for Guillain-Barré syndrome.
Yang M; Rainone A; Shi XQ; Fournier S; Zhang J
Acta Neuropathol Commun; 2014 Jan; 2():5. PubMed ID: 24401681
[TBL] [Abstract][Full Text] [Related]
14. Axonal degeneration in Guillain-Barré syndrome: a reappraisal.
Berciano J
J Neurol; 2021 Oct; 268(10):3728-3743. PubMed ID: 32607643
[TBL] [Abstract][Full Text] [Related]
15. Th1/Th2/Th17/Treg cytokines in Guillain-Barré syndrome and experimental autoimmune neuritis.
Zhang HL; Zheng XY; Zhu J
Cytokine Growth Factor Rev; 2013 Oct; 24(5):443-53. PubMed ID: 23791985
[TBL] [Abstract][Full Text] [Related]
16. Antibodies to gangliosides and ganglioside complexes in Guillain-Barré syndrome and Fisher syndrome: mini-review.
Kaida K; Kusunoki S
J Neuroimmunol; 2010 Jun; 223(1-2):5-12. PubMed ID: 20172612
[TBL] [Abstract][Full Text] [Related]
17. Antibodies to Glycolipids in Guillain-Barré Syndrome, Miller Fisher Syndrome and Related Autoimmune Neurological Diseases.
Kusunoki S
Adv Neurobiol; 2023; 29():479-495. PubMed ID: 36255685
[TBL] [Abstract][Full Text] [Related]
18. IL-23/IL-17 immune axis in Guillain Barré Syndrome: Exploring newer vistas for understanding pathobiology and therapeutic implications.
Debnath M; Nagappa M; Murari G; Taly AB
Cytokine; 2018 Mar; 103():77-82. PubMed ID: 29331587
[TBL] [Abstract][Full Text] [Related]
19. Autoantibody screening in Guillain-Barré syndrome.
Lleixà C; Martín-Aguilar L; Pascual-Goñi E; Franco T; Caballero M; de Luna N; Gallardo E; Suárez-Calvet X; Martínez-Martínez L; Diaz-Manera J; Rojas-García R; Cortés-Vicente E; Turón J; Casasnovas C; Homedes C; Gutiérrez-Gutiérrez G; Jimeno-Montero MC; Berciano J; Sedano-Tous MJ; García-Sobrino T; Pardo-Fernández J; Márquez-Infante C; Rojas-Marcos I; Jericó-Pascual I; Martínez-Hernández E; Morís de la Tassa G; Domínguez-González C; Juárez C; Illa I; Querol L
J Neuroinflammation; 2021 Nov; 18(1):251. PubMed ID: 34719386
[TBL] [Abstract][Full Text] [Related]
20. IL-10 and IFN-gamma in Guillain-Barré syndrome. Network Members of the Swedish Epidemiological Study Group.
Press R; Deretzi G; Zou LP; Zhu J; Fredman P; Lycke J; Link H
J Neuroimmunol; 2001 Jan; 112(1-2):129-38. PubMed ID: 11108941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
